Evaluation of Discrepant Infectious Disease Results in Deceased Organ Donors: Insights From a Retrospective Analysis of Post‐Policy Testing
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Sara Dionne und 3 weiteren Autor:innen. Beteiligte Einrichtung: Eurofins Donor & Product Testing, LLC, Centennial, Colorado, USA. Hauptthemen laut MEDLINE: Tissue Donors, Tissue and Organ Procurement, Donor Selection, Communicable Diseases. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
In 2021, a new policy was implemented by the Organ Procurement Transplant Network requiring Organ Procurement Organizations to draw a repeat blood sample for deceased organ donors if donation had not proceeded within 96‐h after the initial blood sample for screening was obtained. We performed an analysis of over 2600 deceased donor test results, comparing initial results to repeated blood draw results for human immunodeficiency virus, Hepatitis B virus, and Hepatitis C virus serology and nucleic acid test (NAT) tests. This study reviews result discrepancies and explores investigations behind peculiar results.
Methods
Infectious disease results from deceased organ donors were analyzed retrospectively for this study. Donor specimens were collected throughout the United States and tested at eleven laboratories. Food & Drug Administration‐approved donor screening tests were used to determine donor eligibility.
Results
There was a 1.69% discrepancy rate comparing results from repeat blood draw specimens to original specimen results. Of these discrepancies, 0.75% of the donors had results (enzyme‐linked immunoassay and/or NAT) that changed from non‐reactive to reactive. 0.68% of donors had results that changed from reactive to non‐reactive. 0.26% of results changed from Ultrio repeatedly reactive, non‐discriminated to either non‐reactive or reactive.
Conclusion
This study represents that there is more than a 1% chance that discrepant results will be obtained. Despite the low incidence of discrepancies, these rare occurrences can complicate clinical decision‐making, requiring case‐by‐case assessments. We present several cases in which variability in results can make clinical decisions complex with limited information and the inability to perform timely confirmatory testing using tests not required by Organ Procurement Transplant Network regulations. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eurofins Donor & Product Testing, LLC, Centennial, Colorado, USA.
- New England Donor Services, Waltham, Massachusetts, USA.
- Sierra Donor Services, Sacramento, California, USA.
ORCID-Profile: Sara Dionne, Hillary Akana, Chris Curran, Sean Van Slyck
Zitieren
APA
Dionne, S., Akana, H., Curran, C., & Van Slyck, S. (2025). Evaluation of Discrepant Infectious Disease Results in Deceased Organ Donors: Insights From a Retrospective Analysis of Post‐Policy Testing. Transplant Infectious Disease. https://doi.org/10.1111/tid.70055
Vancouver
Dionne S, Akana H, Curran C, Van Slyck S. Evaluation of Discrepant Infectious Disease Results in Deceased Organ Donors: Insights From a Retrospective Analysis of Post‐Policy Testing. Transplant Infectious Disease. 2025. doi:10.1111/tid.70055
BibTeX
@article{Dionne2025,
author = {Dionne, Sara and Akana, Hillary and Curran, Chris and Van Slyck, Sean},
title = {Evaluation of Discrepant Infectious Disease Results in Deceased Organ Donors: Insights From a Retrospective Analysis of Post‐Policy Testing},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70055}
}
EUVIMED